D

Devyser Diagnostics AB
F:OL0

Watchlist Manager
Devyser Diagnostics AB
F:OL0
Watchlist
Price: 10.2 EUR -2.49% Market Closed
Market Cap: 164.8m EUR

Wall Street
Price Targets

OL0 Price Targets Summary
Devyser Diagnostics AB

Wall Street analysts forecast OL0 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OL0 is 15.18 EUR with a low forecast of 14.67 EUR and a high forecast of 16 EUR.

Lowest
Price Target
14.67 EUR
44% Upside
Average
Price Target
15.18 EUR
49% Upside
Highest
Price Target
16 EUR
57% Upside
Devyser Diagnostics AB Competitors:
Price Targets
6990
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
29% Upside
6855
Ascentage Pharma Group International
90% Upside
EXAS
Exact Sciences Corp
1% Downside
ENTA
Enanta Pharmaceuticals Inc
16% Upside
MRNA
Moderna Inc
20% Upside
AUPH
Aurinia Pharmaceuticals Inc
5% Upside
ATX
Amplia Therapeutics Ltd
243% Upside
ACE
Ascelia Pharma AB
157% Upside

Revenue
Forecast

Revenue Estimate
Devyser Diagnostics AB

For the last 5 years the compound annual growth rate for Devyser Diagnostics AB's revenue is 28%. The projected CAGR for the next 4 years is 36%.

28%
Past Growth
36%
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Devyser Diagnostics AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
27%
Average Beat

Net Income
Forecast

Net Income Estimate
Devyser Diagnostics AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
12%
Average Beat
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is OL0's stock price target?
Price Target
15.18 EUR

According to Wall Street analysts, the average 1-year price target for OL0 is 15.18 EUR with a low forecast of 14.67 EUR and a high forecast of 16 EUR.

What is Devyser Diagnostics AB's Revenue forecast?
Projected CAGR
36%

For the last 5 years the compound annual growth rate for Devyser Diagnostics AB's revenue is 28%. The projected CAGR for the next 4 years is 36%.

Back to Top